54K Peptic Ulcers Annually (12.13.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com
Read Article
Drug-Free Remission in Giant Cell Arteritis is Uncommon
A Spanish retrospective registry study of patients with giant cell arteritis (GCA) found that 3-4 years after diagnosis, only 21% of patients with GCA successfully reached the sustained drug-free remission (SDFR). But if SDFR was achieved, the likelihood of experiencing recurrence was
Way Behind in Pediatric Rheumatology
While adult rheumatology fellowships have surged in popularity and become quite competitive, more than half of pediatric rheumatology fellowship positions went unfilled in 2024, according to the National Resident Matching Program (NRMP).
According to Medscape, across all 39
Read Article
FDA has granted Rare Pediatric Disease Designation (RPDD) to a new proprietary investigational drug, 101-PCG-005, a type IA prodrug of dexamethasone targetsing CD206+ macrophages. The intended use is in systemic juvenile idiopathic arthritis (sJIA) or Still's disease .… https://t.co/ErNWlva9Nd https://t.co/gc8cPNs3H1
Dr. John Cush @RheumNow( View Tweet )
Don’t Buy Guitars (12.6.2024)
This year at ACR24, the RheumNow faculty and reporters were prolific, generating >800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days! You can best review and learn ACR24 by A) Rheumatology Roundup; b) Topic Panel videos; and c) Topic podcasts.
Read Article
Challenge in Measuring Cutaneous Lupus Activity and Severity
JAMA Dermatology features a discussion by Drs. McMichael and Frey on measuring lupus skin disease in clinical trials and practice using the validated Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI).
Read Article
J&J has submitted 2 supplemental BLAs applying for FDA approval of guselkumab( Tremfya) for use in juvenile plaque psoriasis & juvenile (>5-6 yrs age) psoriatic arthritis based on several phase 3 RCTs. https://t.co/dAkH219pzN https://t.co/R9yJCSOVJa
Dr. John Cush @RheumNow( View Tweet )
EULAR and the Paediatric Rheumatology European Society (PReS) and FDA now view systemic juvenile idiopathic arthritis and adult-onset Still’s disease as a single entity — Still’s disease; based on overlapping tests, clinical manifestations, complications & response to biologics… https://t.co/OHfcFymdPx https://t.co/Wm2ciKbMtY
Dr. John Cush @RheumNow( View Tweet )
Standardizing Still’s Disease Research: Global Data Harmonization Needed
A recent study presented at #ACR24 convergence highlights significant gaps and inconsistencies in the research of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD).… https://t.co/ugsfRj2fnS https://t.co/UJmNvAMo1c
Dr. John Cush @RheumNow( View Tweet )
ACR24: Rheumatology Roundup
Join Drs. Jack Cush and Artie Kavanaugh as they review 15+ presentations and abstracts from the 2024 ACR Convergence meeting in Washington, DC.
Read Article
Standardizing Still’s Disease Research: Global Data Harmonization Needed
A recent study presented at #ACR24 convergence highlights significant gaps and inconsistencies in the research of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD). Analyzing 195 studies with over 18,000 patients, they found considerable variation
Read Article
A#2529
Disparities in JIA
Outcome documentation, best practices, access to at-risk pts, agency and access
- outcomes initially appeared to worsen - reflection of better documentation
Improvement driven by pt global scores
Disparity gap closed by 17%
#ACR24 @RheumNow https://t.co/oOxs0jIvBK
Eric Dein @ericdeinmd( View Tweet )
Is it safe to administer rotavirus vaccine to infants exposed in utero to TNFi?
Abstract#0806 shows no significant ↑ in the risk of diarrhea-related healthcare events among TNFi-exposed infants who received the vaccine compared to those who did not
@RheumNow #ACR24 https://t.co/HpTCgywE4H
Akhil Sood MD @AkhilSoodMD( View Tweet )
CV risk factors in rheumatic dz patients start in childhood. Patients with PMH of Kawasaki disease are at risk for rca/lmca aneurysms, thrombosis and stroke. Important to consider this with our history taking when pediatric patients transition to adult care! @RheumNow #ACR24 https://t.co/CIp8PjW4vD
Gabriela Martinez Zayas, MD @MartinezZayasMd( View Tweet )
Diagnosis and Management of Kawasaki Disease
The journal Circulation has published a comprehensive overview called “Update on Diagnosis and Management of Kawasaki Disease,” summarizing data published since the 2017 American Heart Association Scientific Statement on Kawasaki… https://t.co/rS5bDneplO https://t.co/nZ0GeIQD0T
Dr. John Cush @RheumNow( View Tweet )
Recomendations for the management of Kawasaki’s disease. Cardiometabolic session, Bryce Binstadt @RheumNow #ACR24 https://t.co/KftwMDYzH1
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
A Polygenic Model for Still's Disease
Adult-onset Still's disease (AOSD) is systemic autoinflammatory disorder of unknown etiology. It is considered among the febrile autoinflammatory etiologies. Now a cohort study shows that AOSD patients may be enriched in germline variants usually limited
Diagnosis and Management of Kawasaki Disease
EurekAlert!
The journal Circulation has published a comprehensive overview called “Update on Diagnosis and Management of Kawasaki Disease,” summarizing data published since the 2017 American Heart Association Scientific Statement on Kawasaki Disease related to diagnostic criteria, risk scores and
Read Article
Overview of Uveitis management of adult & pediatric rheumatology.
- Uveitis accounts for 10% of visual impairment globally
- TNF inhib are effective; w/ IL-6 inhib as 2nd line options https://t.co/CmGuA7W4Ag https://t.co/p5aEQlV7p6
Dr. John Cush @RheumNow( View Tweet )
Happy Diwali (11.1.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read Article
Trends in DMARD Use in Juvenile Arthritis 2001-2022
Arthritis & Rheumatology reports that treatment trends in juvenile idiopathic arthritis (JIA) in the last two decades finds rising use of newer biologic and targeted synthetic DMARDs coupled with a decline in conventional… https://t.co/fEOvjm21lY https://t.co/LfDleabEQS
Dr. John Cush @RheumNow( View Tweet )
Long-term Tofacitinib in Juvenile Idiopathic Arthritis
The long-term safety and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) has been established in an ongoing long term extension (LTE) study.
https://t.co/IKHM6z8iMB https://t.co/O6ig1lTQR4
Dr. John Cush @RheumNow( View Tweet )
Long-term Tofacitinib in Juvenile Idiopathic Arthritis
The long-term safety and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) has been established in an ongoing long term extension (LTE) study.
EULAR/PReS Still's Disease Management Recommendations
Since 2022, EULAR and the Paediatric Rheumatology European Society (PReS) have been working to establish clinical practice guidelines for the diagnostics and management of systemic juvenile idiopathic arthritis (sJIA) and… https://t.co/JZidoWEZSq https://t.co/miwnaw5BZ3
Dr. John Cush @RheumNow( View Tweet )
Adult (133,216) vs Pediatric (955) pts on JAKi - analysis of FAERS shows both @ incr risk for infections & GI AEs. Pediatric pts had more blood and lymphatic disorders, while adults had more CNS and MSK/CTD disorders https://t.co/SKjzANYPSq https://t.co/S6JPYuvSlf
Dr. John Cush @RheumNow( View Tweet )
Recent Blogs
